electroCore (ECOR) and Its Rivals Critical Analysis

electroCore (NASDAQ: ECOR) is one of 47 public companies in the “Electromedical equipment” industry, but how does it contrast to its peers? We will compare electroCore to similar companies based on the strength of its dividends, institutional ownership, profitability, analyst recommendations, risk, valuation and earnings.

Valuation and Earnings

This table compares electroCore and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
electroCore $990,000.00 -$55.82 million -2.52
electroCore Competitors $1.19 billion $88.57 million 16.28

electroCore’s peers have higher revenue and earnings than electroCore. electroCore is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares electroCore and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
electroCore N/A -60.83% -56.24%
electroCore Competitors -128.54% -156.32% -20.95%

Institutional & Insider Ownership

14.1% of electroCore shares are owned by institutional investors. Comparatively, 47.7% of shares of all “Electromedical equipment” companies are owned by institutional investors. 15.5% of shares of all “Electromedical equipment” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for electroCore and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
electroCore 0 1 3 0 2.75
electroCore Competitors 231 658 1259 61 2.52

electroCore presently has a consensus target price of $20.25, suggesting a potential upside of 575.00%. As a group, “Electromedical equipment” companies have a potential upside of 24.50%. Given electroCore’s stronger consensus rating and higher probable upside, equities analysts clearly believe electroCore is more favorable than its peers.

Summary

electroCore peers beat electroCore on 7 of the 12 factors compared.

About electroCore

electroCore, Inc., a bioelectronic medicine company, engages in developing a range of patient-administered non-invasive vagus nerve (VNS) stimulation therapies for the treatment of various conditions in neurology, rheumatology, and other fields. The company is developing gammaCore, a prescription-only non-invasive VNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, which is a handheld delivery system for multi-year use prescribed on a monthly basis. The company was founded in 2005 and is headquartered in Basking Ridge, New Jersey.

Receive News & Ratings for electroCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for electroCore and related companies with MarketBeat.com's FREE daily email newsletter.